IL-23/CGRP Bispecific Antibody
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 30, 2019
Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline
(Fierce Pharma)
- "Lilly disclosed the removal of the drug from its pipeline alongside news of the axing of another bispecific. The second drug to get the chop was an IL-23/CGRP bispecific antibody that Lilly saw as a potential treatment for autoimmune diseases such as inflammatory bowel disease and psoriatic arthritis."
Discontinuation
1 to 1
Of
1
Go to page
1